Tai-Tsang Chen Selected Research

Imatinib Mesylate (Gleevec)

7/2009	Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
6/2006	Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tai-Tsang Chen Research Topics

Disease

8	Neoplasms (Cancer) 11/2023 - 07/2013
6	Melanoma (Melanoma, Malignant) 01/2018 - 10/2010
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2013 - 06/2006
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023
1	Residual Neoplasm 01/2023
1	Multiple Myeloma 01/2023
1	Pleural Effusion (Pleural Effusions) 01/2013
1	Body Weight (Weight, Body) 06/2011
1	Philadelphia Chromosome 06/2006
1	Leukemia 06/2006
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 06/2006
1	Chronic Granulomatous Disease 01/2004

Drug/Important Bio-Agent (IBA)

6	IpilimumabIBA 01/2018 - 10/2010
3	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2018
3	Dasatinib (BMS 354825)FDA Link 01/2013 - 06/2006
2	Immune Checkpoint InhibitorsIBA 11/2023 - 09/2015
2	Dacarbazine (DIC)FDA LinkGeneric 04/2015 - 06/2011
2	Imatinib Mesylate (Gleevec)FDA Link 07/2009 - 06/2006
1	LigandsIBA 11/2023
1	InterferonsIBA 01/2018
1	Glycoproteins (Glycoprotein)IBA 06/2011
1	HLA-A*02:01 antigenIBA 10/2010
1	bcr-abl Fusion ProteinsIBA 06/2006

Therapy/Procedure

5	Immunotherapy 01/2018 - 01/2004
4	Therapeutics 01/2023 - 07/2009
1	Drug Therapy (Chemotherapy) 11/2023
1	Treatment Delay 09/2015